SG11202003280SA - Compositions and methods for the depletion of cd117+ cells - Google Patents
Compositions and methods for the depletion of cd117+ cellsInfo
- Publication number
- SG11202003280SA SG11202003280SA SG11202003280SA SG11202003280SA SG11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA SG 11202003280S A SG11202003280S A SG 11202003280SA
- Authority
- SG
- Singapore
- Prior art keywords
- depletion
- compositions
- cells
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762576572P | 2017-10-24 | 2017-10-24 | |
US201762596569P | 2017-12-08 | 2017-12-08 | |
US201862632967P | 2018-02-20 | 2018-02-20 | |
US201862638053P | 2018-03-02 | 2018-03-02 | |
PCT/US2018/057180 WO2019084064A2 (en) | 2017-10-24 | 2018-10-23 | Compositions and methods for the depletion of cd117+ cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003280SA true SG11202003280SA (en) | 2020-05-28 |
Family
ID=66247007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003280SA SG11202003280SA (en) | 2017-10-24 | 2018-10-23 | Compositions and methods for the depletion of cd117+ cells |
Country Status (13)
Country | Link |
---|---|
US (2) | US10899843B2 (en) |
EP (1) | EP3700568A4 (en) |
JP (2) | JP7280254B2 (en) |
KR (1) | KR20200069364A (en) |
CN (1) | CN111372608B (en) |
AU (1) | AU2018355244A1 (en) |
BR (1) | BR112020008228A2 (en) |
CA (1) | CA3079897A1 (en) |
CO (1) | CO2020004906A2 (en) |
IL (1) | IL274154A (en) |
MX (1) | MX2020004140A (en) |
SG (1) | SG11202003280SA (en) |
WO (1) | WO2019084064A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019084064A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
JP2022530443A (en) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | Anti-CD117 antibody drug conjugate and its use |
JP2022530442A (en) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | Anthracycline antibody drug conjugate and its use |
CN113993550A (en) * | 2019-04-24 | 2022-01-28 | 美真达治疗公司 | Conditioning method for gene therapy |
AU2020261405A1 (en) * | 2019-04-24 | 2021-12-23 | Crispr Therapeutics Ag | Anti-CD117 antibodies and uses thereof |
CA3140180A1 (en) * | 2019-06-04 | 2020-12-10 | Geoffrey O. GILLARD | Methods and compositions for treating autoimmune diseases |
JP2022536094A (en) * | 2019-06-05 | 2022-08-12 | マジェンタ セラピューティクス インコーポレイテッド | Therapies that remove T cells |
JP2023520636A (en) * | 2020-03-16 | 2023-05-18 | マジェンタ セラピューティクス インコーポレイテッド | T cell bispecific binding protein |
WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
WO2023111311A1 (en) | 2021-12-16 | 2023-06-22 | Universität Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
WO2024008910A1 (en) | 2022-07-07 | 2024-01-11 | Cimeio Therapeutics Ag | Antibodies targeting cd117 |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19600589C1 (en) * | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antibody A3C6E2 |
WO1998025957A2 (en) | 1996-12-13 | 1998-06-18 | Human Genome Sciences, Inc. | HUMAN Prt1-LIKE SUBUNIT PROTEIN (hPrt1) AND HUMAN eIF4G-LIKE PROTEIN (p97) GENES |
US6372448B1 (en) | 1998-12-30 | 2002-04-16 | Millennium Pharmaceuticals, Inc. | Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US7329737B2 (en) | 2004-08-03 | 2008-02-12 | Dyax Corp. | Antibodies that bind hK-1 |
WO2007054816A2 (en) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
ATE521366T1 (en) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | APPLICATION OF AMATOXIN CONJUGATES AND PHALLOTOXIN CONJUGATES WITH MACROMOLECLES FOR CANCER THERAPY AND THERAPY OF INFLAMMATION |
PT3255061T (en) | 2006-11-03 | 2021-07-26 | Univ Leland Stanford Junior | Selective immunodepletion of endogenous stem cell niche for engraftment |
CA2694396A1 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binding agents directed to kdr and uses thereof - 035 |
RU2546254C9 (en) | 2008-11-07 | 2015-07-10 | Гэлэкси Биотех, Ллс. | Monoclonal antibodies to fibroblast growth factor receptor 2 |
JO3096B1 (en) | 2008-11-07 | 2017-03-15 | Imclone Llc | Anti-tgf-beta receptor ii antibodies |
HUE050296T2 (en) | 2009-04-08 | 2020-11-30 | Faulstich Heinz Dr | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
CN102858799A (en) | 2010-02-18 | 2013-01-02 | 明治制果药业株式会社 | Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa |
KR101653030B1 (en) | 2010-08-13 | 2016-08-31 | 로슈 글리카트 아게 | Anti-tenascin-c a2 antibodies and methods of use |
EP2436398B1 (en) | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
US20120189612A1 (en) * | 2011-01-25 | 2012-07-26 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
EP3763740A1 (en) * | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
AR086044A1 (en) * | 2011-05-12 | 2013-11-13 | Imclone Llc | ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
FR3008408B1 (en) | 2013-07-11 | 2018-03-09 | Mc Saf | NOVEL ANTIBODY-MEDICAMENT CONJUGATES AND THEIR USE IN THERAPY |
EP3019629A4 (en) | 2013-07-12 | 2017-01-18 | Biogen International Neuroscience GmbH | Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
WO2015057942A1 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides |
EP3065773A1 (en) * | 2013-11-05 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human neutralizing anti-kit antibodies and uses thereof |
JP6606505B2 (en) | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Anti-SIRPα antibody and bispecific macrophage enhancing antibody |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
CA2978064A1 (en) * | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
US10889646B2 (en) | 2015-03-25 | 2021-01-12 | Children's Hospital Medical Center | Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation |
BR112017021536A2 (en) | 2015-04-06 | 2018-07-03 | Harvard College | compositions and methods for nonmyeloablative conditioning |
IL254887B2 (en) | 2015-04-07 | 2023-11-01 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
US10683506B2 (en) * | 2015-04-10 | 2020-06-16 | The Methodist Hospital System | CD117 ligand-drug conjugates for targeted cancer therapy |
MA43017A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | BISPECIFIC ANTIBODIES SPECIFIC TO A TNF CO-STIMULATION RECEPTOR |
JP2019500893A (en) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Antibodies that specifically bind to PD-1 and TIM-3 and uses thereof |
MA46419A (en) | 2016-02-05 | 2018-12-12 | Genmab As | MULTI-SPECIFIC ANTIGEN BINDING MOLECULE WITH BETTER INTERNALIZATION CHARACTERISTICS |
EP3445401A4 (en) | 2016-04-20 | 2019-11-20 | Hangzhou DAC Biotech Co, Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
JP7062647B2 (en) | 2016-06-17 | 2022-05-06 | マジェンタ セラピューティクス インコーポレイテッド | Compositions and Methods for Depleting CD117 + Cells |
US20200188527A1 (en) | 2017-03-31 | 2020-06-18 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
WO2019084064A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
-
2018
- 2018-10-23 WO PCT/US2018/057180 patent/WO2019084064A2/en unknown
- 2018-10-23 US US16/168,823 patent/US10899843B2/en active Active
- 2018-10-23 JP JP2020523244A patent/JP7280254B2/en active Active
- 2018-10-23 BR BR112020008228-7A patent/BR112020008228A2/en unknown
- 2018-10-23 KR KR1020207014624A patent/KR20200069364A/en unknown
- 2018-10-23 MX MX2020004140A patent/MX2020004140A/en unknown
- 2018-10-23 CN CN201880075607.2A patent/CN111372608B/en active Active
- 2018-10-23 AU AU2018355244A patent/AU2018355244A1/en active Pending
- 2018-10-23 SG SG11202003280SA patent/SG11202003280SA/en unknown
- 2018-10-23 EP EP18870545.3A patent/EP3700568A4/en active Pending
- 2018-10-23 CA CA3079897A patent/CA3079897A1/en active Pending
-
2020
- 2020-04-21 CO CONC2020/0004906A patent/CO2020004906A2/en unknown
- 2020-04-22 IL IL274154A patent/IL274154A/en unknown
- 2020-11-24 US US17/103,866 patent/US11958908B2/en active Active
-
2023
- 2023-05-11 JP JP2023078719A patent/JP2023113666A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018355244A1 (en) | 2020-04-09 |
JP2023113666A (en) | 2023-08-16 |
US10899843B2 (en) | 2021-01-26 |
CA3079897A1 (en) | 2019-05-02 |
JP7280254B2 (en) | 2023-05-23 |
US20190153114A1 (en) | 2019-05-23 |
KR20200069364A (en) | 2020-06-16 |
JP2021500375A (en) | 2021-01-07 |
US20210206872A1 (en) | 2021-07-08 |
WO2019084064A4 (en) | 2019-08-08 |
CN111372608B (en) | 2024-07-02 |
MX2020004140A (en) | 2020-08-13 |
BR112020008228A2 (en) | 2020-10-13 |
WO2019084064A3 (en) | 2019-06-20 |
EP3700568A4 (en) | 2021-11-10 |
CN111372608A (en) | 2020-07-03 |
EP3700568A2 (en) | 2020-09-02 |
WO2019084064A2 (en) | 2019-05-02 |
CO2020004906A2 (en) | 2020-05-05 |
US11958908B2 (en) | 2024-04-16 |
IL274154A (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263744A (en) | Compositions and methods for the depletion of cd117 plus cells | |
SG11202003280SA (en) | Compositions and methods for the depletion of cd117+ cells | |
IL263743A (en) | Compositions and methods for the depletion of cells | |
EP3700540A4 (en) | Compositions and methods for the depletion of cd117+ cells | |
IL268058A (en) | Compositions and methods for the depletion of cd137plus cells | |
IL275263A (en) | Compositions and methods for inhibiting t cell exhaustion | |
HK1250481A1 (en) | Modified t cells and methods of making and using the same | |
SG11202004116QA (en) | T cell manufacturing compositions and methods | |
IL255932A (en) | Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers | |
HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
IL269334A (en) | Improved t cell compositions and methods | |
IL268684A (en) | Compositions and methods for immunooncology | |
GB201807325D0 (en) | Compositions and methods | |
IL255480B (en) | Compositions comprising mesenchymal stem cells and uses thereof | |
SG11202004192XA (en) | Compositions and methods for the depletion of cd2+ cells | |
SG11202004294XA (en) | Compositions and methods for the depletion of cd5+ cells | |
IL274524A (en) | Compositions and methods for aquaculturing | |
IL271022A (en) | Compositions and methods for providing cell replacement therapy | |
IL263341A (en) | Stem cell material, compositions, and methods of use | |
IL278201A (en) | Methods and compositions of cytotoxic t cell depletion | |
IL264977A (en) | Methods and compositions for the treatment of melanoma | |
GB201711206D0 (en) | Compositions and methods of cell attachment | |
ZA202004533B (en) | Skin-brightening compositions and methods | |
HK1254866A1 (en) | Novel cell epitopes and combination of cell epitopes for use in the immuno-therapy of myeloma and other cancers | |
IL251588A0 (en) | Methods and compositions for increasing the potency of antifungal agents |